Anaplastik Tiroid Kanseri: Klinik Özellikler, Prognostik Faktörler ve Tedavi Sonuçları

Year 2009, Volume: 42 Issue: 1, 1 - 7, 01.04.2009

Niyazi Karaman Kerim Bora Yılmaz Cihangir Özaslan Mehmet Altınok

Abstract

The objective of this study is to analyse the clinical features, prognostic factors and treatment outcomes of the patients with the diagnosis of anaplastic thyroid carcinoma treated at Ankara Oncology Teaching and Research Hospital between 2001 and 2005. The records of 29 patients with the diagnosis of anaplastic thyroid carcinoma reviewed retrospectiveiy. The association between survivai and age, tumor size, pattern of deveiopment, and type of the resection was analyzed. The median survival of the patients with 5-8 cm tumors and with tumors larger than 8 cm was 2.8 and 4.5 months respectiveiy. The difference was not statistically significant (p= 0.18). The median survivai of the patients under and över 60 years of age was 3.5 and 3.8 months respectiveiy. The difference was not statistically significant (p= 0.65). While the median survival of the patients with transformation from well differentiated thyroid carcinoma was 3.7 months, it was 3.6 months for the patients without any type of well differentiated thyroid carcinoma. The difference was not statistically significant (p= 0.95). The overall survival of the patients with RO, R1 and R2 resections were 3.3, 1 and 3.1 months respectiveiy. The statisticai difference was not significant (p= 0.318). Anaplastic thyroid carcinoma stili carries a dismal prognosis and there is a strong need for innovative treatments.

Keywords

Anaplastic thyroid carcinoma, prognostic factors, treatment outcome.

Anaplastic Thyroid Carcinoma: Clinical Features, Prognostic Factors and Treatment Outcome

Abstract

Bu çalışmada 2001-2005 yılları arasında tedavi edilen 29 tiroid anaplastik karsinom tamlı hastanın klinik özellikleri, prognostik faktörleri ve tedavi sonuçları retrospektif olarak incelenmiştir. Sağkalım ile ilişkisi bakımından; yaş, tümör boyutu, gelişim özellikleri ve rezeksiyon tipleri analiz edilmiştir. Tümör boyutu 5-8 cm olan hastaların sağkalımı 2.8 ay iken, tümörü 8 cm den büyük olan hastaların sağkalımı 4.5 ay olarak bulunmuştur. Aradaki fark istatistiksel olarak anlamlı bulunmamıştır (p= 0.18). Altmış yaş altı ve üstü hastaların ortalama sağkalımları sırasıyla 3.5 ve 3.8 ay olarak bulunmuştur. Aradaki fark istatistiksel olarak anlamlı bulunmamıştır (p= 0.65). iyi diferansiye tiroid karsinomu zemininde gelişen ve tiroid karsinomu hikayesi olmayan hastaların ortalama sağkalımları sırasıyla 3.7 ay ve 3.6 ay olarak bulunmuştur. Aradaki fark istatistiksel olarak anlamlı bulunmamıştır (p= 0.95). RO, R1 ve R2 rezeksiyon uygulanan hastaların ortalama sağkalımları sırasıyla 3.3, 1 ve 3.1 ay olarak bulunmuştur. Aradaki fark istatistiksel olarak anlamlı bulunmamıştır (p= 0.31). Anaplastik tiroid kanserinde lokal kontrol oranlarını artırmaya ve uzak metastaz oranlarını azaltmaya yönelik yeni teknolojilere ve ilaçlara olan ihtiyaç halen devam etmektedir.

Keywords

Anaplastik tiroid kanseri, prognostik faktörler, tedavi sonuçları.

References

• Hundahl S A, Fleming İD, Fremgen AM, Menck HR. A National Cancer Data Base Report on 53856 cases of thyro­ id caroinoma treated in the US,1985-1995. Cancer 1998;83:2438-48.
• Kitamura Y, Shimizu K, Nagahama M, et al. Immediate cau- ses of death in thyroid caroinoma: Clinicopathological analy- sis of 161 fatal cases. J Clin Endocrinol Metab 1999;84: 4043-9.
• Are C, Shaha AR. Anaplastic thyroid caroinoma: Biology, pathogenesis, prognostic factors and treatment approac- hes. Ann Surg Oncol 2006;13:453-64.
• Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC,
• Goepfert H, Samaan NA. Anaplastic carcinoma of the thyro­ id. A clinico-pathologic study of 121 cases. Cancer 1990;66: 321-30.
• Tann RK, Finlay RK, Driscoll D, Bakamjian V, Hicks WL Jr,
• Shedd DP. Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck 1995;17:41-7; Discussion 47-8.
• Mclvor B, Hay İD, Giuffrida DF, et al. Anaplastic thyroid car­ cinoma: A 50-yearexperience ata single institution. Surgery 2001;130:1028-34.
• Grene FL, Page DL, Fleming İD, et al. Thyroid, AJCC can­ cer staging manual. 6,h ed. New York: Springer-Verlag, 2002:77.
• Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: Risk factors and outcome. Surgery 1991;110:956-61; Discussion 961-3.
• Simpsons WJ. Anaplastic thyroid carcinoma: A new appro- ach. Can J Surg 1980;23:25-7.
• Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: Current diagnosis and treatment. Ann Oncol 2000; 11:1083-9.
• Sugitani I, Nobukatsu K, Fujimoto Y, Yanagisava A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. VVorld J Surg 2001;25:617-22.
• Tallroth E, VVallin G, Lundell G, Lowhagen T, Einhorn J. Multimodality treatment in anaplastic giant celi carcinoma. Cancer 1987;60:1428-31.
• Us-Krasovec M, Golouh fi, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Açta Cytol 1996;40:953-8.
• Sugino K, Ito K, Mimura T, et al. The important role of ope- rations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-8.
• Heigh Pl, Ituarte PH, VIu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant ehe- motheraphy and irradiation is associated with prolonged survival. Cancer 2001;91:2235-42.
• Tenvvall J, Lundell G, VVahlberg P, et al. Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperf- ractionated radiotheraphy and surgery. Br J Cancer 2002; 86:1848-53.
• Kim JH, Leiper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation the- raphy. Cancer 1987;60:2372-5.
• Asakawa H, Koboyashi T, Komoike Y, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997;17:2757-62.
• Ain KB, Egorin MJ, DeSimono PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using 96 hour infusion. Thyroid 2000;10:587-94.
• Satake S, Sugavvara I, Watanabe M, Takami H. Lack of point mutation of human DNA topoisomerase II in multidrug- resistant anaplastic thyroid carcinoma celi lines. Cancer 1997;116:33-9.
• Shimaoka K, Schoenfeld D, DeWys WD, Creech RH, DeConti fi. A randomized trial of doxorubicin versus doxo- rubicin plus cisplatin in patients with advanced thyroid car­ cinoma. Cancer 1985;56:2155-60.
• Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic- Grazio S, VodnikA. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg 2001;27:260-4.